Table 1 Baseline characteristics of the study population
Patients receiving VKA (n = 1008) | Patients receiving NOAC (n = 552) | P value | |
|---|---|---|---|
Median age (IQR) | 78.00 (71.00–84.00) | 80.00 (72.00–86.00) | < 0.001 |
Male (%) | 645 (64.0) | 314 (56.9) | 0.007 |
Oral anticoagulation | < 0.001 | ||
Apixaban (%) | 302 (54.7) | ||
Dabigatran (%) | 80 (14.5) | ||
Rivaroxaban (%) | 170 (30.8) | ||
VKA (%) | 1008 (100.0) | ||
Income group (quartiles) | < 0.001 | ||
1st (lowest) | 382 (37.9) | 143 (25.9) | |
2nd | 297 (29.5) | 165 (29.9) | |
3rd | 208 (20.6) | 159 (28.8) | |
4th (highest) | 121 (12.0) | 85 (15.4) | |
Comorbidity | |||
Hypertension | 914 (90.7) | 494 (89.5) | 0.454 |
Previous stroke (%) | 175 (17.4) | 102 (18.5) | 0.629 |
Previous bleeding (%) | 256 (25.4) | 122 (22.1) | 0.164 |
Heart failure (%) | 395 (39.2) | 195 (35.3) | 0.147 |
Ischemic heart disease (%) | 440 (43.7) | 231 (42.9) | 0.492 |
Peripheral artery disease (%) | 101 (10.0) | 63 (11.4) | 0.391 |
Diabetes (%) | 260 (25.8) | 141 (25.5) | 0.962 |
Liver disease (%) | 28 (2.8) | 19 (3.4) | 0.563 |
Alcohol abuse (%) | 38 (3.8) | 31 (5.6) | 0.117 |
Comedication | |||
ADPi (%) | 164 (16.3) | 107 (19.4) | 0.138 |
Aspirin (%) | 537 (53.3) | 277 (50.2) | 0.264 |
Statin (%) | 503 (49.9) | 275 (49.8) | 1.000 |
Beta-blocker (%) | 582 (57.7) | 303 (54.9) | 0.302 |
RASi (%) | 524 (52.0) | 294 (53.3) | 0.667 |
NSAID (%) | 116 (11.5) | 69 (12.5) | 0.619 |